A Open-label, Randomized , Prospective, Phase 2 Trial of Neoadjuvant Chemotherapy Combined With Small Dose of Apatinib in the Treatment of Early Triple-negative Breast Cancer

Trial Profile

A Open-label, Randomized , Prospective, Phase 2 Trial of Neoadjuvant Chemotherapy Combined With Small Dose of Apatinib in the Treatment of Early Triple-negative Breast Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Apatinib (Primary) ; Carboplatin; Docetaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top